A Study of LY4257496 in Participants With Cancer (OMNIRAY) (NCT07114601)
A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (32 Sites)
Showing the first 25 of 32 sites.
- City of Hope — Duarte, California
- University of California, Los Angeles (UCLA) — Santa Monica, California
- Stanford University Medical Center — Stanford, California
- Biogenix Molecular, LLC — Miami, Florida
- Moffitt — Tampa, Florida
- Emory University School of Medicine - Winship Cancer Institute — Atlanta, Georgia
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
- BAMF Health Inc. — Grand Rapids, Michigan
- Washington University — St Louis, Missouri
- New York University (NYU) Langone Medical Center — New York, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Texas Oncology - DFW (Sammons CC) — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Juravinski Cancer Centre — Hamilton,
- Lady Davis Institute for Medical Research Jewish General Hospital — Montreal,
- Sunnybrook Health Sciences Centre — Toronto,
- Princess Margaret Hospital — Toronto,
- Peking Union Medical College Hospital of Chinese Academy of Medical Sciences — Beijing,
- Tianjin Cancer Hospital Airport Hospital — Tianjin,
- Institut Curie — Paris,
- Institut de Cancerologie de l'Ouest - site St-Herblain — Saint-Herblain,
- Universitaetsklinikum Erlangen — Erlangen,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.